Amin Yakubu

Amin Yakubu

Auto-generated profile, based on publicly available information

Amin Yakubu

Columbia University

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2023 in Neuromuscular Diseases
Verified
Journal Article
Open access
PDF file
NSNatalia Павлович Suponeva
Natalia Павлович Suponeva
AAA. S. Arestova
A. S. Arestova
EMEvgeniya A Melnik
Evgeniya A Melnik
AZA. A. Zimin
A. A. Zimin
AZAlexandr Zaytsev
Alexandr Zaytsev
MPMichael Piradov
Michael Piradov
Background. The use of rating scales and questionnaires is essential in an evaluation of disease course, treatment response, the disability level and quality of life in patients with chronic inflammatory demyelinating polyneuropathy. The Medical Research Council (MRC) scale and its modification Medical Research Council sum score (MRCss) are widely used for measurement of motor deficit in patients with neuromuscular disorders. However, its usage is limited by the absence of the validated version for Russian-speaking patients.Aim. To validate MRCss scale in patients with chronic inflammatory demyelinating polyneuropathy with development of a Russian version.Materials and methods. We enrolled 50 patients with chronic inflammatory demyelinating polyneuropathy (25 with typical chronic inflammatory demyelinating polyneuropathy and 25 with Lewis–Sumner syndrome). At the first step we conducted linguocultural ratification according to the standard protocol. At the second step the psychometric parameters were evaluated, such as reliability, validity and sensitivity.Results. The developed Russian version of MRCss scale demonstrated the high level of reliability, validity and sensitivity.Conclusion. As a result, we developed a validated Russian version of MRCss scale, recommended for clinical practice and research.

29 December 2021 in Neuromuscular Diseases
Verified
Journal Article
Open access
PDF file
АAА. S. Arestova
А. S. Arestova
EMEvgeniya A Melnik
Evgeniya A Melnik
AZAlexandr Zaytsev
Alexandr Zaytsev
AZA. A. Zimin
A. A. Zimin
АYА. Yakubu
А. Yakubu
MPMichael Piradov
Michael Piradov
Background. Chronic inflammatory demyelinating polyneuropathy (CIDP) is a treatable dysimmune polyneuropathy. An objective response for pathogenic therapy is essential in diagnosis and management of CIDP. For proper assessment of patient’s complaints and evaluation of disease progression, it is recommended to use validated scales and questionnaires. The paper presents the results of the first step of Inflammatory Neuropathy Cause and Treatment (INCAT) validation in patients with CIDP.Objective: the development of the Russian version of the INCAT scale and its linguocultural ratification.Materials and methods. 15 patients with definite CIDP (according to EFNS/PNS criteria) were enrolled. Linguocultural ratification was conducted according to the standard protocol.Results. The Russian version of the INCAT scale was developed.Conclusion. We conducted the first stage of INCAT scale validation in patients with CIDP.

26 December 2024 in Neuromuscular Diseases
Verified
Journal Article
Open access
PDF file
NSNatalia Павлович Suponeva
Natalia Павлович Suponeva
AAA. S. Arestova
A. S. Arestova
EMEvgeniya A Melnik
Evgeniya A Melnik
AZA. A. Zimin
A. A. Zimin
ANA. M. Narbut
A. M. Narbut
MPMichael Piradov
Michael Piradov
Background. A clinical application of scales and questionnaires is essential for the objective evaluation of treatment response, disease course, quality of life and the disability level in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Neuropathy Impairment Score (NIS) has become widespread in epidemiological and clinical studies of various polyneuropathies, including CIDP. However, its application in Russia is limited by the absence of its validated version for Russian-speaking patients. Aim. To develop the Russian validated version of the NIS for its application in patients with CIDP. Materials and methods. The study involved 50 patients with CIDP (25 with multifocal variant of CIDP (Lewis–Sumner syndrome) and 25 with typical CIDP). The validation process included two stages: translation and linguocultural ratification of the scale according to the standard protocol and an assessment of its psychometric properties, such as reliability, validity and sensitivity. Results. The developed Russian version of the NIS demonstrated the high level of reliability, sensitivity and validity. Conclusion. The validated Russian version of the NIS can be recommended for application in research and clinical practice.

6 March 2026 in Neuromuscular Diseases
Verified
Journal Article
Open access
PDF file
NSNatalia Павлович Suponeva
Natalia Павлович Suponeva
AAAlina S. Arestova
Alina S. Arestova
EMEvgeniya A Melnik
Evgeniya A Melnik
AZA. A. Zimin
A. A. Zimin
ANA. M. Narbut
A. M. Narbut
MPMichael Piradov
Michael Piradov
Background. Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common type of dysimmune neuropathy, and it can lead to either permanent or temporary disability in about half of patients. Objective assessment of functional impairment is essential for monitoring therapeutic outcomes and disease progression in CIDP. The Inflammatory Rasch-built Overall Disability Scale (I-RODS) is one of the most valuable tools for assessing disability in CIDP patients and can be used in both clinical research and routine practice. In this article, we present the results of the validation process for this scale in Russian individuals with CIDP. Aim. To translate and validate the I-RODS for use in Russian patients with CIDP. Materials and methods. The study enrolled 50 cases of CIDP, evenly distributed between the typical variant and Lewis–Sumner syndrome. We performed linguocultural adaptation of the original version of the I-RODS using a standard protocol, after which we assessed the psychometric properties of the Russian version (i.e., its sensitivity, reliability and validity). Results. Psychometric evaluation demonstrated good reliability, sensitivity, and validity of the Russian I-RODS adaptation. Conclusion. We validated the Russian-language adaptation of the I-RODS, which can be applied in for both clinical practice and research.

19 August 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
KOKenneth Ofori
Kenneth Ofori
AYAmin Yakubu
Amin Yakubu
ARAlex J Rai
Alex J Rai
IgA nephropathy (IgAN) is an autoimmune disease and the most common primary glomerulonephritis. The four-hit hypothesis describes mechanism of the disease, from synthesis of galactose deficient IgA (GD-IgA), to recognition of GD-IgA by anti-glycan antibodies and deposition of the formed immune complex in the mesangium. Complement and coagulation cascade activation ensues, resulting in mesangial activation and cytokine release, podocyte injury, mesangial sclerosis and tubulointerstitial damage. Currently, there is no disease cure, and 30-40% of patients progress to end stage renal disease. Using complementary bioinformatic approaches, we demonstrate different levels of deviation of the transcriptome of the glomerulus in IgAN from normal, with the aim of identifying therapeutic targets. Approaches used herein include, deconvolution of the transcriptome to estimate immune constitution, co-regulation-based functional analysis of differentially expressed genes, modular co-expression analysis, network analysis of metabolic pathways and differential gene correlation analysis. We describe the immune composition in IgAN and the relatively low fold changes of the abundance of different immune cells and strength of immune signatures compared with control. Additionally, we identify enrichment of the intestinal network for IgA synthesis, repression of expression and dysregulation of networks of amino acid metabolism and PPAR signaling pathways in IgAN glomeruli. We also find loss of correlation between expression of matrix synthesizing and matrix degrading genes in IgAN. We conclude by discussing how therapies based on some nodes in these altered pathways described have been shown to be efficacious in IgAN and/or other inflammatory diseases and the potential of others in effective treatment.

29 July 2026 in The Joint Commission Journal on Quality and Patient Safety
Verified
Journal Article
Closed access
JHJack J. Huang
Jack J. Huang
NBNicole M. Benson
Nicole M. Benson
AYAmin Yakubu
Amin Yakubu
BRBoyu Ren
Boyu Ren
ABAlisa Busch
Alisa Busch